ENSC
Ensysce Biosciences·NASDAQ
--
--(--)
--
--(--)
Signals Analysis
Bullish signal 1
Bearish signal 5
High Gross Profit Margin
Significant Revenue Decline
Significant Net Income Decline
EPS Below Expectations
Revenue Below Expectations
Consecutive Revenue Decline
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ENSC
Ensysce Biosciences, Inc.
A clinical stage pharmaceutical company seeking to develop innovative solutions for severe pain relief while reducing the fear of and the potential for misuse, abuse, and overdose
7946 Ivanhoe Avenue, Suite 201, La Jolla, California 92037
--
Ensysce Biosciences, Inc., was incorporated in Delaware in April 2003. The company is a clinical-stage biotechnology company that leverages its proprietary technology platform to develop safer prescription drugs. Using its trypsin-activated abuse protection and multidrug abuse resistance platform, the company is developing a new class of powerful, tamper-proof opioids that can prevent drug abuse and overdose. Ensysce's products are expected to provide a safer option to treat severe pain and help prevent deaths from opioid abuse, thereby reducing human and economic costs.
Company Financials
EPS
ENSC has released its 2025 Q2 earnings. EPS was reported at -0.79, versus the expected -1.28, beating expectations. The chart below visualizes how ENSC has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ENSC has released its 2025 Q3 earnings report, with revenue of 493.10K, reflecting a YoY change of -85.58%, and net profit of -3.73M, showing a YoY change of -663.51%. The Sankey diagram below clearly presents ENSC's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
